Trademark: CRISPR BY DESIGN 2248235
Word
CRISPR BY DESIGN
ID
2248235
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
22 September 2021
Registration Date
22 September 2021
Renewal Date
22 September 2031
Owner(s)
Service
Goods and Services:
Class 5:
Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics; gene therapy products, namely, biological preparations based on engineered cells for medical use in immuno oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, including neurological disorders, huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, alzheimer's, parkinson's, ataxia, autism, epilepsy, pain, and also including cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders.
Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics; gene therapy products, namely, biological preparations based on engineered cells for medical use in immuno oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, including neurological disorders, huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, alzheimer's, parkinson's, ataxia, autism, epilepsy, pain, and also including cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders.
Class 42:
Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; molecular diagnostic services for medical research purposes.
Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; molecular diagnostic services for medical research purposes.